Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629801 | 1.00 | CA12 (0.46) | CA12CA1CA9PREPTDP1 | |
| SCHEMBL6371459 | 0.87 | CA12 (0.47) | CA12CA1CA9PREPTDP1 | |
| SCHEMBL2106653 | 0.85 | CA12 (0.51) | CA12CA1CA9PREPTDP1 | |
| SCHEMBL12731852 | 0.83 | CA12 (0.50) | CA12CA1CA9PREPTDP1 | |
| SCHEMBL29989644 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPTSHR | |
| SCHEMBL31401810 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPTDP1 | |
| SCHEMBL27087789 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPTSHR | |
| SCHEMBL5239636 | 0.81 | CA12 (0.49) | CA12CA1CA9PREPTDP1 | |
| SCHEMBL9013589 | 0.80 | CA12 (0.47) | CA12CA1CA9PREPALDH1A1 | |
| SCHEMBL2313565 | 0.79 | CA12 (0.46) | CA12CA1CA9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177391-A1 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4482825-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | President and Fellows of Harvard College (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023196714-A9 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023196714-A9 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023196714-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196714-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11174246-B2 | Direct AMPK activators | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2018035128-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | disclosed |
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177391-A1 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | DDR2, DDR1, DDRGK1 | CA12 4866/4885CA1 4865/4885CA9 4849/4885 |
| US-11174246-B2 | Direct AMPK activators | PRKAA1, PRKAG1, PRKAB1 | CA12 4620/4885CA1 3464/4885CA9 3210/4885 |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | CA12 4620/4885CA1 3464/4885CA9 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.